Savvy Psychopharmacology

Strategies for managing medication-induced hyperprolactinemia

Author and Disclosure Information

 

References

Less data exist on managing hyperprolactinemia that is induced by a medication other than an antipsychotic; however, it seems reasonable that the same strategies could be implemented. Specifically, for SSRI–induced hyperprolactinemia, if clinically appropriate, switching to or adding an alternative antidepressant that may be prolactin-sparing, such as mirtazapine or bupropion, could be attempted.8 One study found that fluoxetine-induced galactorrhea ceased within 10 days of discontinuing the medication.30

CASE CONTINUED

Because Ms. E has been on the same medication regimen for 3 years and recently developed galactorrhea, it seems unlikely that her hyperprolactinemia is medication-induced. However, a tumor-related cause is less likely because the prolactin level is <100 ng/mL. Based on the literature, the only possible medication-induced cause of her galactorrhea is risperidone. Ms. E agrees to a trial of adjunctive oral aripiprazole, 5 mg/d, with close monitoring of her type 2 diabetes mellitus. Because of the long elimination half-life of aripiprazole, 1 month is required to monitor for improvement in galactorrhea. Ms. E is advised to use breast pads as a nonpharmacologic strategy in the interim. After 1 month of treatment, Ms. E denies galactorrhea symptoms and no longer requires the use of breast pads.

Related Resource

  • Peuskens J, Pani L, Detraux J, et al. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421-453.

Drug Brand Names

Amitriptyline Elavil
Amoxapine Asendin
Aripiprazole Abilify
Brexpiprazole Rexulti
Bromocriptine Cycloset
Bupropion Wellbutrin
Cabergoline Dostinex
Cariprazine Vraylar
Chlorpromazine Thorazine
Citalopram Celexa
Clomipramine Anafranil
Clorgyline Aurorix
Clozapine Clozaril
Desipramine Norpramin
Escitalopram Lexapro
Fluoxetine Prozac
Fluvoxamine Luvox
Haloperidol Haldol
Lamotrigine Lamictal
Lithium Lithobid
Medroxyprogesterone Provera
Metformin Glucophage
Methyldopa Aldomet
Metoclopramide Reglan
Milnacipran Savella
Mirtazapine Remeron
Olanzapine Zyprexa
Paliperidone Invega
Paroxetine Paxil
Pramipexole Mirapex
Prazosin Minipress
Prochlorperazine Compazine
Quetiapine Seroquel
Reserpine Raudixin
Risperidone Risperdal
Sertraline Zoloft
Tetrabenazine Xenazine
Thioridazine Mellaril
Thiothixene Navane
Valproic acid Depakote
Venlafaxine Effexor
Verapamil Calan
Ziprasidone Geodon

Pages

Recommended Reading

4 Ways to help your patients with schizophrenia quit smoking
MDedge Psychiatry
Neurodegenerative aspects of psychiatric disorders
MDedge Psychiatry
NIMH launches interactive statistics section on its website
MDedge Psychiatry
Schizophrenia and gender: Do neurosteroids account for differences?
MDedge Psychiatry
Virtual reality–based CBT may improve social participation in psychosis
MDedge Psychiatry
Inaccurate depictions of inpatient psychiatry foster stigma
MDedge Psychiatry
Delayed treatment for psychosis can have ‘deleterious’ effects
MDedge Psychiatry
Decompensation in a 51-year-old woman with schizophrenia
MDedge Psychiatry
Social recovery therapy, early intervention ‘superior’ in first-episode psychosis
MDedge Psychiatry
Mental health reporting laws: A false answer to gun violence
MDedge Psychiatry